These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25098457)

  • 1. [Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].
    Caletti C; Granata S; Tomei P; Lupo A; Zaza G
    G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors.
    Zaza G; Tomei P; Ria P; Granata S; Boschiero L; Lupo A
    Clin Dev Immunol; 2013; 2013():403280. PubMed ID: 24151517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibitors and renal allograft: Yin and Yang.
    Zaza G; Granata S; Tomei P; Masola V; Gambaro G; Lupo A
    J Nephrol; 2014 Oct; 27(5):495-506. PubMed ID: 24804854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus and everolimus in kidney transplantation.
    Moes DJ; Guchelaar HJ; de Fijter JW
    Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of mTOR inhibitors in adult solid organ transplantation.
    Ventura-Aguiar P; Campistol JM; Diekmann F
    Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
    Bachmann F; Glander P; Budde K; Bachmann C
    J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous pemphigoid induced by m-TOR inhibitors in renal transplant recipients.
    Atzori L; Conti B; Zucca M; Pau M
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1626-30. PubMed ID: 25174440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
    Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
    Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
    Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
    Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
    Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
    Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe everolimus-associated pneumonitis in a renal transplant recipient.
    Alexandru S; Ortiz A; Baldovi S; Milicua JM; Ruíz-Escribano E; Egido J; Plaza JJ
    Nephrol Dial Transplant; 2008 Oct; 23(10):3353-5. PubMed ID: 18658177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
    Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
    Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
    Gonzalez-Vilchez F; Vazquez de Prada JA; Paniagua MJ; Gomez-Bueno M; Arizon JM; Almenar L; Roig E; Delgado J; Lambert JL; Perez-Villa F; Sanz-Julve ML; Crespo-Leiro M; Segovia J; Lopez-Granados A; Martinez-Dolz L; Mirabet S; Escribano P; Diaz-Molina B; Farrero M; Blasco T
    Int J Cardiol; 2014 Jan; 171(1):15-23. PubMed ID: 24309084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
    Nashan B
    Clin Transplant; 2013; 27 Suppl 25():16-29. PubMed ID: 23909498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.